A new lawsuit is calling attention to an unusual move by drug maker Actavis PLC that the New York attorney general says is designed to preserve sales of a brand-name medication for Alzheimer's disease.. The state attorney general's office filed suit Monday against Dublin-based Actavis in federal court in New York, seeking to block the company's publicly stated plan to stop selling Namenda tablets, which are given twice daily. The suit accuses Actavis of forcing patients to switch to a once-daily formulation of the same drug,...
  